New Treatment for Fragile X Syndrome by Correcting a Gene Mistake
Therapeutic Potential of Rescued FMR1 Mis-Splicing in Fragile X Syndrome
['FUNDING_R01'] · UNIV OF MASSACHUSETTS MED SCH WORCESTER · NIH-11093322
This research explores a new way to treat Fragile X Syndrome by fixing a specific error in the FMR1 gene using special genetic tools.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF MASSACHUSETTS MED SCH WORCESTER (nih funded) |
| Locations | 1 site (WORCESTER, UNITED STATES) |
| Trial ID | NIH-11093322 on ClinicalTrials.gov |
What this research studies
Fragile X Syndrome is a common inherited cause of intellectual disability and autism, caused by a problem with the FMR1 gene that stops it from working correctly. Our team discovered that in some people with Fragile X, the FMR1 gene makes a faulty, mis-spliced RNA molecule. We are developing special genetic tools called antisense oligonucleotides (ASOs) that can correct this mistake. By fixing the mis-splicing, we hope to restore the FMR1 gene's normal function and reduce the symptoms of the syndrome.
Who could benefit from this research
Good fit: This research is relevant for individuals diagnosed with Fragile X Syndrome, particularly those whose FMR1 gene shows the specific mis-splicing error identified in this work.
Not a fit: Patients with Fragile X Syndrome whose FMR1 gene does not exhibit this particular mis-splicing error may not benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this approach could lead to a new therapy that directly addresses the genetic cause of Fragile X Syndrome, potentially improving intellectual function and reducing autism-like behaviors.
How similar studies have performed: Antisense oligonucleotide (ASO) therapies have shown success in treating other genetic disorders, but this specific application to correct FMR1 mis-splicing in Fragile X Syndrome is a novel approach.
Where this research is happening
WORCESTER, UNITED STATES
- UNIV OF MASSACHUSETTS MED SCH WORCESTER — WORCESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RICHTER, JOEL D — UNIV OF MASSACHUSETTS MED SCH WORCESTER
- Study coordinator: RICHTER, JOEL D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Aran-Duchenne disease, Autistic Disorder